{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,21]],"date-time":"2026-11-21T17:18:35Z","timestamp":1795281515982,"version":"4.10.3"},"reference-count":64,"publisher":"BMJ","issue":"10","license":[{"start":{"date-parts":[[2022,4,27]],"date-time":"2022-04-27T00:00:00Z","timestamp":1651017600000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100010269","name":"Wellcome","doi-asserted-by":"publisher","award":["WT107492Z"],"award-info":[{"award-number":["WT107492Z"]}],"id":[{"id":"10.13039\/100010269","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Spanish National Health Institute","award":["PID2019-105378RB-I00"],"award-info":[{"award-number":["PID2019-105378RB-I00"]}]},{"DOI":"10.13039\/501100004587","name":"Instituto de Salud Carlos III","doi-asserted-by":"publisher","award":["CD19\/00109"],"award-info":[{"award-number":["CD19\/00109"]}],"id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000289","name":"Cancer Research UK","doi-asserted-by":"publisher","award":["A17196 and A31287"],"award-info":[{"award-number":["A17196 and A31287"]}],"id":[{"id":"10.13039\/501100000289","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000289","name":"Cancer Research UK","doi-asserted-by":"publisher","award":["A21339"],"award-info":[{"award-number":["A21339"]}],"id":[{"id":"10.13039\/501100000289","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000289","name":"Cancer Research UK","doi-asserted-by":"publisher","award":["A23983"],"award-info":[{"award-number":["A23983"]}],"id":[{"id":"10.13039\/501100000289","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000289","name":"Cancer Research UK","doi-asserted-by":"publisher","award":["C18342\/A23390"],"award-info":[{"award-number":["C18342\/A23390"]}],"id":[{"id":"10.13039\/501100000289","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000289","name":"Cancer Research UK","doi-asserted-by":"publisher","award":["C9380\/A18084"],"award-info":[{"award-number":["C9380\/A18084"]}],"id":[{"id":"10.13039\/501100000289","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000289","name":"Cancer Research UK","doi-asserted-by":"publisher","award":["C9380\/A26813"],"award-info":[{"award-number":["C9380\/A26813"]}],"id":[{"id":"10.13039\/501100000289","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001659","name":"Deutsche Forschungsgemeinschaft","doi-asserted-by":"publisher","award":["DFG, HA 8754\/1-1"],"award-info":[{"award-number":["DFG, HA 8754\/1-1"]}],"id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004837","name":"Ministerio de Ciencia e Innovaci\u00f3n","doi-asserted-by":"publisher","award":["BES-2017-081286"],"award-info":[{"award-number":["BES-2017-081286"]}],"id":[{"id":"10.13039\/501100004837","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["RO1DK56621 and RO1DK128289"],"award-info":[{"award-number":["RO1DK56621 and RO1DK128289"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000265","name":"Medical Research Council","doi-asserted-by":"publisher","award":["MR\/K0019494\/1 and MR\/R023026\/1"],"award-info":[{"award-number":["MR\/K0019494\/1 and MR\/R023026\/1"]}],"id":[{"id":"10.13039\/501100000265","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["Gut"],"accepted":{"date-parts":[[2022,3,17]]},"published-print":{"date-parts":[[2022,10]]},"abstract":"<jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>Hepatocellular carcinoma (HCC) is increasingly associated with non-alcoholic steatohepatitis (NASH). HCC immunotherapy offers great promise; however, recent data suggests NASH-HCC may be less sensitive to conventional immune checkpoint inhibition (ICI). We hypothesised that targeting neutrophils using a CXCR2 small molecule inhibitor may sensitise NASH-HCC to ICI therapy.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Design<\/jats:title>\n                    <jats:p>Neutrophil infiltration was characterised in human HCC and mouse models of HCC. Late-stage intervention with anti-PD1 and\/or a CXCR2 inhibitor was performed in murine models of NASH-HCC. The tumour immune microenvironment was characterised by imaging mass cytometry, RNA-seq and flow cytometry.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Neutrophils expressing CXCR2, a receptor crucial to neutrophil recruitment in acute-injury, are highly represented in human NASH-HCC. In models of NASH-HCC lacking response to ICI, the combination of a CXCR2 antagonist with anti-PD1 suppressed tumour burden and extended survival. Combination therapy increased intratumoural XCR1\n                      <jats:sup>+<\/jats:sup>\n                      dendritic cell activation and CD8\n                      <jats:sup>+<\/jats:sup>\n                      T cell numbers which are associated with anti-tumoural immunity, this was confirmed by loss of therapeutic effect on genetic impairment of myeloid cell recruitment, neutralisation of the XCR1-ligand XCL1 or depletion of CD8\n                      <jats:sup>+<\/jats:sup>\n                      T cells. Therapeutic benefit was accompanied by an unexpected increase in tumour-associated neutrophils (TANs) which switched from a protumour to anti-tumour progenitor-like neutrophil phenotype. Reprogrammed TANs were found in direct contact with CD8\n                      <jats:sup>+<\/jats:sup>\n                      T cells in clusters that were enriched for the cytotoxic anti-tumoural protease granzyme B. Neutrophil reprogramming was not observed in the circulation indicative of the combination therapy selectively influencing TANs.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>CXCR2-inhibition induces reprogramming of the tumour immune microenvironment that promotes ICI in NASH-HCC.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/gutjnl-2021-326259","type":"journal-article","created":{"date-parts":[[2022,5,5]],"date-time":"2022-05-05T13:21:31Z","timestamp":1651756891000},"page":"2093-2106","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":201,"title":["CXCR2 inhibition enables NASH-HCC immunotherapy"],"prefix":"10.1136","volume":"71","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6443-2396","authenticated-orcid":false,"given":"Jack","family":"Leslie","sequence":"first","affiliation":[{"name":"Newcastle Fibrosis Research Group, Biosciences Institute, Faculty of Medical Sciences, Newcastle University, Newcastle Upon Tyne, UK"},{"name":"The Newcastle University Centre for Cancer, Newcastle University, Newcastle upon Tyne, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John B G","family":"Mackey","sequence":"additional","affiliation":[{"name":"Cancer Research UK Beatson Institute, Glasgow, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Jamieson","sequence":"additional","affiliation":[{"name":"Cancer Research UK Beatson Institute, Glasgow, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erik","family":"Ramon-Gil","sequence":"additional","affiliation":[{"name":"Newcastle Fibrosis Research Group, Biosciences Institute, Faculty of Medical Sciences, Newcastle University, Newcastle Upon Tyne, UK"},{"name":"The Newcastle University Centre for Cancer, Newcastle University, Newcastle upon Tyne, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas M","family":"Drake","sequence":"additional","affiliation":[{"name":"Cancer Research UK Beatson Institute, Glasgow, UK"},{"name":"MRC Centre for Inflammation Research, The Queen\u2019s Medical Research Institute, University of Edinburgh, Edinburgh, UK"},{"name":"Institute of Cancer Sciences, University of Glasgow, Glasgow, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4825-024X","authenticated-orcid":false,"given":"Fr\u00e9d\u00e9ric","family":"Fercoq","sequence":"additional","affiliation":[{"name":"Cancer Research UK Beatson Institute, Glasgow, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William","family":"Clark","sequence":"additional","affiliation":[{"name":"Cancer Research UK Beatson Institute, Glasgow, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathryn","family":"Gilroy","sequence":"additional","affiliation":[{"name":"Cancer Research UK Beatson Institute, Glasgow, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ann","family":"Hedley","sequence":"additional","affiliation":[{"name":"Cancer Research UK Beatson Institute, Glasgow, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Colin","family":"Nixon","sequence":"additional","affiliation":[{"name":"Cancer Research UK Beatson Institute, Glasgow, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saimir","family":"Luli","sequence":"additional","affiliation":[{"name":"Newcastle Fibrosis Research Group, Biosciences Institute, Faculty of Medical Sciences, Newcastle University, Newcastle Upon Tyne, UK"},{"name":"The Newcastle University Centre for Cancer, Newcastle University, Newcastle upon Tyne, UK"},{"name":"Preclinical In Vivo Imaging Facility, Faculty of Medical Sciences, Newcastle University, Newcastle upon Tyne, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maja","family":"Laszczewska","sequence":"additional","affiliation":[{"name":"Newcastle Fibrosis Research Group, Biosciences Institute, Faculty of Medical Sciences, Newcastle University, Newcastle Upon Tyne, UK"},{"name":"The Newcastle University Centre for Cancer, Newcastle University, Newcastle upon Tyne, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0288-6314","authenticated-orcid":false,"given":"Roser","family":"Pinyol","sequence":"additional","affiliation":[{"name":"Translational Research in Hepatic Oncology, Liver Unit, IDIBAPS, Hospital Cl\u00ednic, University of Barcelona, Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roger","family":"Esteban-Fabr\u00f3","sequence":"additional","affiliation":[{"name":"Translational Research in Hepatic Oncology, Liver Unit, IDIBAPS, Hospital Cl\u00ednic, University of Barcelona, Barcelona, Spain"},{"name":"Mount Sinai Liver Cancer Program, Division of Liver Diseases, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, New York, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0617-8833","authenticated-orcid":false,"given":"Catherine E","family":"Willoughby","sequence":"additional","affiliation":[{"name":"Translational Research in Hepatic Oncology, Liver Unit, IDIBAPS, Hospital Cl\u00ednic, University of Barcelona, Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philipp K","family":"Haber","sequence":"additional","affiliation":[{"name":"Mount Sinai Liver Cancer Program, Division of Liver Diseases, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, New York, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carmen","family":"Andreu-Oller","sequence":"additional","affiliation":[{"name":"Translational Research in Hepatic Oncology, Liver Unit, IDIBAPS, Hospital Cl\u00ednic, University of Barcelona, Barcelona, Spain"},{"name":"Mount Sinai Liver Cancer Program, Division of Liver Diseases, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, New York, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1133-2134","authenticated-orcid":false,"given":"Mohammad","family":"Rahbari","sequence":"additional","affiliation":[{"name":"Division of Chronic Inflammation and Cancer, German Cancer Research Centre, Heidelberg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chaofan","family":"Fan","sequence":"additional","affiliation":[{"name":"Division of Chronic Inflammation and Cancer, German Cancer Research Centre, Heidelberg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dominik","family":"Pfister","sequence":"additional","affiliation":[{"name":"Division of Chronic Inflammation and Cancer, German Cancer Research Centre, Heidelberg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shreya","family":"Raman","sequence":"additional","affiliation":[{"name":"Department of Pathology, Newcastle Upon Tyne Hospitals NHS Foundation Trust, Newcastle Upon Tyne, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Niall","family":"Wilson","sequence":"additional","affiliation":[{"name":"Newcastle Fibrosis Research Group, Biosciences Institute, Faculty of Medical Sciences, Newcastle University, Newcastle Upon Tyne, UK"},{"name":"The Newcastle University Centre for Cancer, Newcastle University, Newcastle upon Tyne, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0751-1407","authenticated-orcid":false,"given":"Miryam","family":"M\u00fcller","sequence":"additional","affiliation":[{"name":"Cancer Research UK Beatson Institute, Glasgow, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amy","family":"Collins","sequence":"additional","affiliation":[{"name":"Newcastle Fibrosis Research Group, Biosciences Institute, Faculty of Medical Sciences, Newcastle University, Newcastle Upon Tyne, UK"},{"name":"The Newcastle University Centre for Cancer, Newcastle University, Newcastle upon Tyne, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3592-7469","authenticated-orcid":false,"given":"Daniel","family":"Geh","sequence":"additional","affiliation":[{"name":"Newcastle Fibrosis Research Group, Biosciences Institute, Faculty of Medical Sciences, Newcastle University, Newcastle Upon Tyne, UK"},{"name":"The Newcastle University Centre for Cancer, Newcastle University, Newcastle upon Tyne, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"Fuller","sequence":"additional","affiliation":[{"name":"Flow Cytometry Facility, Biosciences Institute, Faculty of Medical Sciences, Newcastle University, Newcastle Upon Tyne, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"McDonald","sequence":"additional","affiliation":[{"name":"Flow Cytometry Facility, Biosciences Institute, Faculty of Medical Sciences, Newcastle University, Newcastle Upon Tyne, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gillian","family":"Hulme","sequence":"additional","affiliation":[{"name":"Flow Cytometry Facility, Biosciences Institute, Faculty of Medical Sciences, Newcastle University, Newcastle Upon Tyne, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"Filby","sequence":"additional","affiliation":[{"name":"Flow Cytometry Facility, Biosciences Institute, Faculty of Medical Sciences, Newcastle University, Newcastle Upon Tyne, UK"},{"name":"Innovation, Methodology and Innovation (IMA) theme, Biosciences Institute, Faculty of Medical Sciences, Newcastle University, Newcastle upon Tyne, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xabier","family":"Cortes-Lavaud","sequence":"additional","affiliation":[{"name":"Cancer Research UK Beatson Institute, Glasgow, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Noha-Ehssan","family":"Mohamed","sequence":"additional","affiliation":[{"name":"Cancer Research UK Beatson Institute, Glasgow, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catriona A","family":"Ford","sequence":"additional","affiliation":[{"name":"Cancer Research UK Beatson Institute, Glasgow, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ximena L","family":"Raffo Iraolagoitia","sequence":"additional","affiliation":[{"name":"Cancer Research UK Beatson Institute, Glasgow, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amanda J","family":"McFarlane","sequence":"additional","affiliation":[{"name":"Cancer Research UK Beatson Institute, Glasgow, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Misti V","family":"McCain","sequence":"additional","affiliation":[{"name":"The Newcastle University Centre for Cancer, Newcastle University, Newcastle upon Tyne, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rachel A","family":"Ridgway","sequence":"additional","affiliation":[{"name":"Cancer Research UK Beatson Institute, Glasgow, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edward W","family":"Roberts","sequence":"additional","affiliation":[{"name":"Cancer Research UK Beatson Institute, Glasgow, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simon T","family":"Barry","sequence":"additional","affiliation":[{"name":"Bioscience, Early Oncology, AstraZeneca, Macclesfield, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gerard J","family":"Graham","sequence":"additional","affiliation":[{"name":"Chemokine Research Group, Institute of Infection, Immunity and Inflammation, University of Glasgow, Glasgow, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mathias","family":"Heikenw\u00e4lder","sequence":"additional","affiliation":[{"name":"Division of Chronic Inflammation and Cancer, German Cancer Research Centre, Heidelberg, Germany"},{"name":"Department of Surgery, University Hospital Mannheim, Medical Faculty Mannheim, University of Heidelberg, Heidelberg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helen L","family":"Reeves","sequence":"additional","affiliation":[{"name":"The Newcastle University Centre for Cancer, Newcastle University, Newcastle upon Tyne, UK"},{"name":"Translational and Clinical Research Institute, Faculty of Medical Sciences, Newcastle University, Newcastle upon Tyne, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Josep M","family":"Llovet","sequence":"additional","affiliation":[{"name":"Translational Research in Hepatic Oncology, Liver Unit, IDIBAPS, Hospital Cl\u00ednic, University of Barcelona, Barcelona, Spain"},{"name":"Mount Sinai Liver Cancer Program, Division of Liver Diseases, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, New York, USA"},{"name":"Instituci\u00f3 Catalana de Recerca i Estudis Avan\u00e7ats (ICREA), Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leo M","family":"Carlin","sequence":"additional","affiliation":[{"name":"Cancer Research UK Beatson Institute, Glasgow, UK"},{"name":"Institute of Cancer Sciences, University of Glasgow, Glasgow, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6120-1581","authenticated-orcid":false,"given":"Thomas G","family":"Bird","sequence":"additional","affiliation":[{"name":"Cancer Research UK Beatson Institute, Glasgow, UK"},{"name":"MRC Centre for Inflammation Research, The Queen\u2019s Medical Research Institute, University of Edinburgh, Edinburgh, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Owen J","family":"Sansom","sequence":"additional","affiliation":[{"name":"Cancer Research UK Beatson Institute, Glasgow, UK"},{"name":"Institute of Cancer Sciences, University of Glasgow, Glasgow, UK"},{"name":"Beatson Institute for Cancer Research, Glasgow, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Derek A","family":"Mann","sequence":"additional","affiliation":[{"name":"Newcastle Fibrosis Research Group, Biosciences Institute, Faculty of Medical Sciences, Newcastle University, Newcastle Upon Tyne, UK"},{"name":"The Newcastle University Centre for Cancer, Newcastle University, Newcastle upon Tyne, UK"},{"name":"Fibrofind Ltd, William Leech Building, Medical School, Newcastle University, Newcastle upon Tyne, UK"},{"name":"Department of Gastroenterology and Hepatology, School of Medicine, Ko\u00e7 University, Istanbul, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2022,4,27]]},"reference":[{"key":"2025090715300733000_71.10.2093.1","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21660"},{"key":"2025090715300733000_71.10.2093.2","doi-asserted-by":"publisher","DOI":"10.1016\/j.cgh.2018.05.057"},{"key":"2025090715300733000_71.10.2093.3","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2013.08.011"},{"key":"2025090715300733000_71.10.2093.4","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1016\/j.medj.2021.03.002","article-title":"The therapeutic landscape of hepatocellular carcinoma","volume":"2","author":"Gallage","year":"2021","journal-title":"Med"},{"key":"2025090715300733000_71.10.2093.5","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1915745"},{"key":"2025090715300733000_71.10.2093.6","doi-asserted-by":"crossref","DOI":"10.1001\/jamaoncol.2020.4564","article-title":"Efficacy and safety of nivolumab plus ipilimumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib: the CheckMate 040 randomized clinical trial","volume":"6","author":"Yau","year":"2020","journal-title":"JAMA Oncol"},{"key":"2025090715300733000_71.10.2093.7","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.19.01307"},{"key":"2025090715300733000_71.10.2093.8","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(21)00604-5"},{"key":"2025090715300733000_71.10.2093.9","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-021-03362-0"},{"key":"2025090715300733000_71.10.2093.10","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2021.06.008"},{"key":"2025090715300733000_71.10.2093.11","doi-asserted-by":"publisher","DOI":"10.1136\/gutjnl-2021-324339"},{"key":"2025090715300733000_71.10.2093.12","doi-asserted-by":"publisher","DOI":"10.1038\/s41571-019-0222-4"},{"key":"2025090715300733000_71.10.2093.13","doi-asserted-by":"publisher","DOI":"10.1038\/nrc.2016.52"},{"key":"2025090715300733000_71.10.2093.14","doi-asserted-by":"crossref","unstructured":"Geh D , Leslie J , Rumney R . Neutrophils as potential therapeutic targets in hepatocellular carcinoma. Nat Rev Gastroenterol Hepatol 2022:1\u201317.","DOI":"10.1038\/s41575-021-00568-5"},{"key":"2025090715300733000_71.10.2093.15","doi-asserted-by":"publisher","DOI":"10.1152\/ajpgi.90272.2008.-The"},{"key":"2025090715300733000_71.10.2093.16","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-021-96076-2"},{"key":"2025090715300733000_71.10.2093.17","doi-asserted-by":"publisher","DOI":"10.1038\/bjc.2017.386"},{"key":"2025090715300733000_71.10.2093.18","doi-asserted-by":"crossref","DOI":"10.1016\/S0168-8278(20)30632-2","article-title":"Cabozantinib enhances the efficacy and immune modulatory activity of anti-PD1 therapy in a syngeneic mouse model of hepatocellular carcinoma","volume":"73","author":"Esteban-Fabr\u00f3","year":"2020","journal-title":"J Hepatol"},{"key":"2025090715300733000_71.10.2093.19","doi-asserted-by":"publisher","DOI":"10.1080\/2162402X.2016.1232221"},{"key":"2025090715300733000_71.10.2093.20","doi-asserted-by":"publisher","DOI":"10.1093\/carcin\/bgs123"},{"key":"2025090715300733000_71.10.2093.21","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccr.2009.06.017"},{"key":"2025090715300733000_71.10.2093.22","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aba4448","article-title":"Transcriptomic profiling across the nonalcoholic fatty liver disease spectrum reveals gene signatures for steatohepatitis and fibrosis","volume":"12","author":"Govaere","year":"2020","journal-title":"Sci Transl Med"},{"key":"2025090715300733000_71.10.2093.23","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2021.04.049"},{"key":"2025090715300733000_71.10.2093.24","doi-asserted-by":"publisher","DOI":"10.1172\/JCI61067"},{"key":"2025090715300733000_71.10.2093.25","doi-asserted-by":"publisher","DOI":"10.4143\/crt.2014.321"},{"key":"2025090715300733000_71.10.2093.26","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-10-0483"},{"key":"2025090715300733000_71.10.2093.27","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccell.2016.04.014"},{"key":"2025090715300733000_71.10.2093.28","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aax0428","article-title":"Targeting cellular heterogeneity with CXCR2 blockade for the treatment of therapy-resistant prostate cancer","volume":"11","author":"Li","year":"2019","journal-title":"Sci Transl Med"},{"key":"2025090715300733000_71.10.2093.29","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-021-01355-1"},{"key":"2025090715300733000_71.10.2093.30","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccr.2013.10.009"},{"key":"2025090715300733000_71.10.2093.31","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-21-0369"},{"key":"2025090715300733000_71.10.2093.32","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2020-000586","article-title":"Granzyme B is correlated with clinical outcome after PD-1 blockade in patients with stage IV non-small-cell lung cancer","volume":"8","author":"Hurkmans","year":"2020","journal-title":"J Immunother Cancer"},{"key":"2025090715300733000_71.10.2093.33","doi-asserted-by":"publisher","DOI":"10.3892\/ijo_figS0788"},{"key":"2025090715300733000_71.10.2093.34","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2003-04-1069"},{"key":"2025090715300733000_71.10.2093.35","doi-asserted-by":"publisher","DOI":"10.1016\/j.cellimm.2007.07.004"},{"key":"2025090715300733000_71.10.2093.36","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.00924"},{"key":"2025090715300733000_71.10.2093.37","doi-asserted-by":"publisher","DOI":"10.1016\/J.IMMUNI.2019.01.009"},{"key":"2025090715300733000_71.10.2093.38","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-021-01344-3"},{"key":"2025090715300733000_71.10.2093.39","doi-asserted-by":"crossref","first-page":"2329","DOI":"10.1016\/j.celrep.2018.07.097","article-title":"Identification of an early Unipotent neutrophil progenitor with pro-tumoral activity in mouse and human bone marrow","volume":"24","author":"Zhu","year":"2018","journal-title":"Cell Rep"},{"key":"2025090715300733000_71.10.2093.40","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-021-22973-9"},{"key":"2025090715300733000_71.10.2093.41","doi-asserted-by":"publisher","DOI":"10.2174\/138161209788453202"},{"key":"2025090715300733000_71.10.2093.42","doi-asserted-by":"publisher","DOI":"10.1096\/fj.13-229591"},{"key":"2025090715300733000_71.10.2093.43","doi-asserted-by":"crossref","DOI":"10.3390\/biom10030456","article-title":"Lactoferrin\u2019s anti-cancer properties: safety, selectivity, and wide range of action","volume":"10","author":"Cutone","year":"2020","journal-title":"Biomolecules"},{"key":"2025090715300733000_71.10.2093.44","doi-asserted-by":"publisher","DOI":"10.1002\/hep.27732"},{"key":"2025090715300733000_71.10.2093.45","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2017.06.007"},{"key":"2025090715300733000_71.10.2093.46","doi-asserted-by":"publisher","DOI":"10.1172\/JCI91190"},{"key":"2025090715300733000_71.10.2093.47","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2020.07.026"},{"key":"2025090715300733000_71.10.2093.48","doi-asserted-by":"publisher","DOI":"10.1146\/annurev-pathol-020712-164023"},{"key":"2025090715300733000_71.10.2093.49","doi-asserted-by":"publisher","DOI":"10.1146\/annurev-immunol-020711-074942"},{"key":"2025090715300733000_71.10.2093.50","unstructured":"Mackey JBG , McFarlane AJ , Jamieson T . Maturation, developmental site, and pathology dictate murine neutrophil function. bioRxiv."},{"key":"2025090715300733000_71.10.2093.51","doi-asserted-by":"publisher","DOI":"10.1002\/hep.29904"},{"key":"2025090715300733000_71.10.2093.52","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-17-0950"},{"key":"2025090715300733000_71.10.2093.53","doi-asserted-by":"publisher","DOI":"10.1038\/s41575-019-0145-7"},{"key":"2025090715300733000_71.10.2093.54","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2020-000725"},{"key":"2025090715300733000_71.10.2093.55","doi-asserted-by":"publisher","DOI":"10.1186\/s12967-020-02404-x"},{"key":"2025090715300733000_71.10.2093.56","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2020.01802","article-title":"Chemokines in non-alcoholic fatty liver disease: a systematic review and network meta-analysis","volume":"11","author":"Pan","year":"2020","journal-title":"Front Immunol"},{"key":"2025090715300733000_71.10.2093.57","doi-asserted-by":"publisher","DOI":"10.1038\/s41423-020-00560-0"},{"key":"2025090715300733000_71.10.2093.58","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2016.05.041"},{"key":"2025090715300733000_71.10.2093.59","doi-asserted-by":"publisher","DOI":"10.1016\/j.smim.2017.12.004"},{"key":"2025090715300733000_71.10.2093.60","doi-asserted-by":"crossref","unstructured":"Tang KH , Li S , Khodadadi-Jamayran A . Combined inhibition of SHP2 and CXCR1\/2 promotes anti-tumor T cell response in NSCLC. Cancer Discov 2021.","DOI":"10.1101\/2021.03.21.436338"},{"key":"2025090715300733000_71.10.2093.61","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.130850","article-title":"Neutrophil content predicts lymphocyte depletion and anti-PD1 treatment failure in NSCLC","volume":"4","author":"Kargl","year":"2019","journal-title":"JCI Insight"},{"key":"2025090715300733000_71.10.2093.62","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.126853","article-title":"Inhibiting myeloid-derived suppressor cell trafficking enhances T cell immunotherapy","volume":"4","author":"Sun","year":"2019","journal-title":"JCI Insight"},{"key":"2025090715300733000_71.10.2093.63","doi-asserted-by":"publisher","DOI":"10.1189\/jlb.1HI0715-289R"},{"key":"2025090715300733000_71.10.2093.64","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra2021808"}],"container-title":["Gut"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/gutjnl-2021-326259","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,7]],"date-time":"2025-09-07T22:30:21Z","timestamp":1757284221000},"score":1,"resource":{"primary":{"URL":"https:\/\/gut.bmj.com\/lookup\/doi\/10.1136\/gutjnl-2021-326259"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,4,27]]},"references-count":64,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2022,9,7]]},"published-print":{"date-parts":[[2022,10]]}},"alternative-id":["10.1136\/gutjnl-2021-326259"],"URL":"https:\/\/doi.org\/10.1136\/gutjnl-2021-326259","relation":{"has-preprint":[{"id-type":"doi","id":"10.1101\/2022.02.24.481779","asserted-by":"object"}]},"ISSN":["0017-5749","1468-3288"],"issn-type":[{"value":"0017-5749","type":"print"},{"value":"1468-3288","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,4,27]]}}}